S118: LONG-TERM SAFETY AND EFFICACY OF VOXELOTOR FOR PATIENTS WITH SICKLE CELL DISEASE: RESULTS FROM AN OPEN-LABEL EXTENSION OF THE PHASE 3 HOPE TRIAL

por Achebe, M, Nduba, V, Hassab, H, Alkindi, S, Brown, R, Telfer, P, Biemond, B, Gordeuk, V, Lipato, T, Tonda, M, Gray, S, Howard, J
Publicado 2022

Evaluating the implementation of a multi-level mHealth study to improve hydroxyurea utilization in sickle cell disease

por Hankins, J. S, Potter, M. B, Fernandez, M. E, Melvin, C, DiMartino, L, Jacobs, S. R, Bosworth, H. B, King, A. A, Simon, J, Glassberg, J. A, Kutlar, A, Gordeuk, V. R, Shah, N, Baumann, A. A, Klesges, L. M
Publicado 2023

5610845 A PHASE 1 STUDY OF CSL888 (HEMOPEXIN) IN ADULT PATIENTS WITH SICKLE CELL DISEASE

por Biemond, B.J., Shore, B.J., Wilson, F., Jochems, J., Lindqvist, L.M., Jung, K., Gentinetta, T., Costin, S., Kato, G.J., Eleftheriou, P., Fok, H., Wahab, E., Leung, P.M., Sharif, J., Boucher, A., Fitzgerald, R., Keese-Adu, R., Azbell, R., Liles, D., Bergmann, S., Lanzkron, S., Gordeuk, V.
Publicado 2023